Skyrizi Side Effects
Generic name: risankizumab
Note: This document contains side effect information about risankizumab. Some dosage forms listed on this page may not apply to the brand name Skyrizi.
Applies to risankizumab: parenteral injection for iv infusion, parenteral injection for sub-q use.
Side effects include:
Adverse reactions (≥1%) in patients with plaque psoriasis and psoriatic arthritis: upper respiratory infection, headache, fatigue, injection site reaction, tinea infection.
Adverse reactions (>3%) in patients receiving induction treatment for Crohn disease: upper respiratory infection, headache, arthralgia.
Adverse reactions (>3%) in patients receiving maintenance treatment for Crohn disease: arthralgia, injection site reaction, abdominal pain, anemia, pyrexia, back pain, arthropathy, urinary tract infection.
For Healthcare Professionals
Applies to risankizumab: intravenous solution, subcutaneous kit, subcutaneous solution.
Gastrointestinal
Common (1% to 10%): Abdominal pain[Ref]
Dermatologic
Common (1% to 10%): Tinea infections (e.g., tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection)
Uncommon (0.1% to 1%): Folliculitis, urticaria
Postmarketing: Eczema, rash[Ref]
Hematologic
Common (1% to 10%): Anemia[Ref]
Hypersensitivity
Hypersensitivity
Common (1% to 10%): Hypersensitivity reactions[Ref]
Immunologic
Very common (10% or more): Immunogenicity (24%), infections (e.g., cellulitis, osteomyelitis, sepsis, herpes zoster) (22%)[Ref]
Local
Common (1% to 10%): Injection site reactions (e.g., bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth)[Ref]
Musculoskeletal
Common (1% to 10%): Arthralgia, arthropathy, back pain[Ref]
Nervous system
Common (1% to 10%): Headache (e.g., tension headache, sinus headache, cervicogenic headache)[Ref]
Other
Common (1% to 10%): Fatigue, asthenia, pyrexia[Ref]
Respiratory
Very common (10% or more): Upper respiratory infections (e.g., respiratory tract infection [viral, bacterial, unspecified], sinusitis [including acute], rhinitis, nasopharyngitis, pharyngitis [including viral], tonsillitis) (up to 13%)[Ref]
Frequently asked questions
- What are monoclonal antibodies?
- What's the dosing schedule for Skyrizi?
- Does Skyrizi cause cancer?
- Can you drink alcohol while taking Skyrizi?
- Skyrizi vs Humira for plaque psoriasis - How do they compare?
- Is Skyrizi approved for treating psoriatic arthritis?
- Does Skyrizi cause hair loss?
- Who makes Skyrizi and where is it made?
- Skyrizi vs Ilumya. What’s the difference?
More about Skyrizi (risankizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (42)
- Drug images
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
References
1. (2024) "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, SUPPL-32
2. (2019) "Product Information. Skyrizi (risankizumab)." AbbVie US LLC
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.